LifeSci Capital initiated coverage of Compass Therapeutics (CMPX) with an Outperform rating and $10 price target
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPX:
- Compass Therapeutics management to meet with Piper Sandler
- Compass Therapeutics Announces Public Offering to Raise $112.5M
- Compass Therapeutics 33.3M share Spot Secondary priced at $3.00
- Compass Therapeutics announces common stock offering, no amount given
- Compass Therapeutics price target raised to $12 from $10 at Guggenheim